The periosteum is now widely recognized as a homeostatic and therapeutic target for actions of sex steroids and intermittent parathyroid hormone (PTH) administration. Androgens and PTH stimulate while estrogens suppress periosteal expansion in a number of experimental models. However, low estrogen concentrations may also promote periosteal expansion by direct actions or indirectly by permitting the stimulatory effects of androgens or mechanical stimulation. The mechanisms by which sex steroids and PTH influence this key skeletal envelope are not known. We have found that sex steroids and PTH have common properties in protecting periosteal osteoblasts from apoptosis. In sharp contrast, estrogens as compared to androgens and PTH have opposing actions to regulate the recruitment of early periosteal osteoblast progenitors. The estrogen receptor (ER) itself has important actions both as a site for liganded estrogen interaction and as an independent modulator. The liganded ER attenuates periosteal osteoblast differentiation while in its unoccupied configuration, it potentiates periosteal osteoblast differentiation. We hypothesize that sex steroids and PTH promote the survival of mature periosteal osteoblasts. In parallel, estrogens suppress whereas androgens, intermittent PTH, and the unliganded ER promote periosteal expansion by exerting opposite actions on the proliferation and differentiation of early periosteal osteoblast progenitors. The effect of combined estrogen and PTH administration to the periosteal surface reflects the relative balance between prolongation of osteoblast survival, an action shared by both hormones, and opposing actions of PTH and estrogens on proliferation and differentiation of progenitor periosteal osteoblasts. To test these hypotheses, we will examine whether estrogens versus androgens, PTH and unliganded ER differentially regulate differentiation and proliferation of distinct populations of periosteal osteoblast precursors. The contribution of pro-differentiating versus anti-apoptotic actions of sex steroids, intermittent PTH and the combination of PTH and estrogens to the periosteal expansion that occurs with skeletal maturity will be investigated in vivo. Finally, we will establish in vivo that the osteoblast-specific actions of estrogens account for their effects on periosteal bone mass. Understanding the cellular and molecular mechanisms by which sex steroids and PTH act and interact to regulate periosteal preservation or expansion, could lead to new therapeutic approaches to the treatment of osteoporosis.

Public Health Relevance

The periosteum is now widely recognized as a homeostatic and therapeutic target for actions of sex steroids and intermittent parathyroid hormone (PTH) administration. Androgens and PTH stimulate while estrogens suppress periosteal expansion in a number of experimental models. We hypothesize that sex steroids and PTH promote the survival of mature periosteal osteoblasts. In parallel, estrogens suppress whereas androgens, intermittent PTH, and the unliganded ER promote periosteal expansion by exerting opposite actions on the proliferation and differentiation of early periosteal osteoblast progenitors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR054447-05
Application #
8220988
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Chen, Faye H
Project Start
2008-04-01
Project End
2013-08-14
Budget Start
2012-02-01
Budget End
2013-08-14
Support Year
5
Fiscal Year
2012
Total Cost
$302,968
Indirect Cost
$114,789
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Krevvata, Maria; Silva, Barbara C; Manavalan, John S et al. (2014) Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood 124:2834-46
Kode, Aruna; Manavalan, John S; Mosialou, Ioanna et al. (2014) Leukaemogenesis induced by an activating ?-catenin mutation in osteoblasts. Nature 506:240-4
Yoshikawa, Yoshihiro; Kode, Aruna; Xu, Lili et al. (2011) Genetic evidence points to an osteocalcin-independent influence of osteoblasts on energy metabolism. J Bone Miner Res 26:2012-25
Rached, Marie-Therese; Kode, Aruna; Xu, Lili et al. (2010) FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab 11:147-60
Rached, Marie-Therese; Kode, Aruna; Silva, Barbara C et al. (2010) FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest 120:357-68